INSERM U943, Paris, France.
PLoS One. 2013;8(3):e59014. doi: 10.1371/journal.pone.0059014. Epub 2013 Mar 21.
Several attempts have been made to determine HIV-1 resistance from genotype resistance testing. We compare scoring methods for building weighted genotyping scores and commonly used systems to determine whether the virus of a HIV-infected patient is resistant.
Three statistical methods (linear discriminant analysis, support vector machine and logistic regression) are used to determine the weight of mutations involved in HIV resistance. We compared these weighted scores with known interpretation systems (ANRS, REGA and Stanford HIV-db) to classify patients as resistant or not. Our methodology is illustrated on the Forum for Collaborative HIV Research didanosine database (N = 1453). The database was divided into four samples according to the country of enrolment (France, USA/Canada, Italy and Spain/UK/Switzerland). The total sample and the four country-based samples allow external validation (one sample is used to estimate a score and the other samples are used to validate it). We used the observed precision to compare the performance of newly derived scores with other interpretation systems. Our results show that newly derived scores performed better than or similar to existing interpretation systems, even with external validation sets. No difference was found between the three methods investigated. Our analysis identified four new mutations associated with didanosine resistance: D123S, Q207K, H208Y and K223Q.
We explored the potential of three statistical methods to construct weighted scores for didanosine resistance. Our proposed scores performed at least as well as already existing interpretation systems and previously unrecognized didanosine-resistance associated mutations were identified. This approach could be used for building scores of genotypic resistance to other antiretroviral drugs.
已经有几种尝试从基因型耐药检测来确定 HIV-1 耐药性。我们比较了构建加权基因型评分的评分方法和常用系统,以确定 HIV 感染患者的病毒是否具有耐药性。
使用三种统计方法(线性判别分析、支持向量机和逻辑回归)来确定涉及 HIV 耐药性的突变的权重。我们将这些加权评分与已知的解释系统(ANRS、REGA 和斯坦福 HIV-db)进行比较,以确定患者是否耐药。我们的方法学在协作性 HIV 研究论坛(Forum for Collaborative HIV Research)的地达诺辛(didanosine)数据库(N=1453)上进行了说明。该数据库根据注册国家(法国、美国/加拿大、意大利和西班牙/英国/瑞士)分为四个样本。总样本和四个基于国家的样本允许外部验证(一个样本用于估计评分,其他样本用于验证)。我们使用观察精度来比较新衍生评分与其他解释系统的性能。我们的结果表明,新衍生的评分表现优于或与现有的解释系统相当,即使在外部验证集上也是如此。在所研究的三种方法之间没有发现差异。我们的分析确定了与地达诺辛耐药性相关的四个新突变:D123S、Q207K、H208Y 和 K223Q。
我们探索了三种统计方法构建地达诺辛耐药性加权评分的潜力。我们提出的评分至少与现有的解释系统一样好,并且确定了以前未识别的与地达诺辛耐药性相关的突变。这种方法可用于构建对其他抗逆转录病毒药物的基因型耐药评分。